Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK Study of [14C]-GBT021601 in Healthy Participants
NCT05718687Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osivelotor in sickle cell disease (SCD), sponsored by Pfizer. Primary endpoints: GBT021601 Concentration in Whole Blood and Plasma at 4920 hours, 14C-GBT021601 Total Radioactivity Concentration at 4920 hours and 10 more. Started Dec 2022; status: completed.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05718687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718687.